BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30813149)

  • 1. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer.
    Chang SC; Lai YC; Hung JC; Chang CY
    Medicine (Baltimore); 2019 Feb; 98(8):e14463. PubMed ID: 30813149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
    Topkan E; Parlak C; Topuk S; Pehlivan B
    BMC Cancer; 2012 Oct; 12():502. PubMed ID: 23113946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy.
    Gul K; Mehmet K; Meryem A
    Clin Nutr; 2017 Aug; 36(4):1022-1028. PubMed ID: 27373496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters.
    Topkan E; Yavuz MN; Onal C; Yavuz AA
    Lung Cancer; 2009 Mar; 63(3):393-9. PubMed ID: 18691789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial.
    Alshawa A; Cadena AP; Stephen B; Reddy A; Mendoza TR; McQuinn L; Lawhorn K; Zarifa A; Bernhardt AM; Fessaheye S; Warneke CL; Chang JY; Naing A
    Invest New Drugs; 2021 Aug; 39(4):1113-1122. PubMed ID: 33580845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral glutamine supplementation reduces radiotherapy- induced esophagitis in lung cancer patients.
    Gul K; Muge A; Taner A; Sehri E
    Asian Pac J Cancer Prev; 2015; 16(1):53-8. PubMed ID: 25640390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.
    Al-Halabi H; Paetzold P; Sharp GC; Olsen C; Willers H
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):803-10. PubMed ID: 26104934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
    Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
    Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
    Ninomiya K; Ichihara E; Hotta K; Sone N; Murakami T; Harada D; Oze I; Kubo T; Tanaka H; Kuyama S; Kishino D; Bessho A; Harita S; Katsui K; Tanimoto M; Kiura K
    Clin Lung Cancer; 2017 Mar; 18(2):245-249. PubMed ID: 27847247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study.
    Algara M; Rodríguez N; Viñals P; Lacruz M; Foro P; Reig A; Quera J; Lozano J; Fernández-Velilla E; Membrive I; Dengra J; Sanz X
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):342-9. PubMed ID: 17531398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, three-arm, randomized trial of EGCG for preventing radiation-induced esophagitis in lung cancer patients receiving radiotherapy.
    Zhao H; Jia L; Chen G; Li X; Meng X; Zhao X; Xing L; Zhu W
    Radiother Oncol; 2019 Aug; 137():186-191. PubMed ID: 30898322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma.
    Giuliani ME; Lindsay PE; Kwan JY; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
    Clin Lung Cancer; 2015 May; 16(3):216-20. PubMed ID: 25532963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.
    Chen L; Huang J; Wu W; Ta S; Xie X
    Int J Cardiovasc Imaging; 2019 Jun; 35(6):1009-1017. PubMed ID: 30941563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Kuroda Y; Sekine I; Sumi M; Sekii S; Takahashi K; Inaba K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Murakami N; Morota M; Mayahara H; Ito Y; Tamura T; Nemoto K; Itami J
    Technol Cancer Res Treat; 2013 Aug; 12(4):333-9. PubMed ID: 23369154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer.
    Nijkamp J; Rossi M; Lebesque J; Belderbos J; van den Heuvel M; Kwint M; Uyterlinde W; Vogel W; Sonke JJ
    Radiother Oncol; 2013 Jan; 106(1):118-23. PubMed ID: 23219463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneously modulated accelerated radiation therapy reduces severe oesophageal toxicity in concomitant chemoradiotherapy of locally advanced non-small-cell lung cancer.
    Chajon E; Bellec J; Castelli J; Corre R; Kerjouan M; Le Prisé E; De Crevoisier R
    Br J Radiol; 2015; 88(1056):20150311. PubMed ID: 26414340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.